| Donald Lee Harker, DO | |
|
1111 Duff Ave, Ames, IA 50010-5745 | |
| (515) 239-2151 | |
| Not Available |
| Full Name | Donald Lee Harker |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 15 Years |
| Location | 1111 Duff Ave, Ames, Iowa |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508179615 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | DO-04525 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Broadlawns Medical Center | Des moines, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Broadlawns Medical Center | 3678466166 | 207 |
News Archive
In a paper published in the current issue of the journal Molecular Biology and Evolution , Arizona State University biochemists Jason Raymond, Christopher Staples and Robert Blankenship and Rice University's Janet Siefert do an analysis of the genomes of a large group of bacteria and archaea, comparing in particular similar genes that produce the protein nitrogenase.
Teva Pharmaceutical Industries Ltd. announced today the launch of Olanzapine and Fluoxetine Capsules USP 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg, and 12 mg/50 mg, the Company's generic equivalent of Symbyax.
Orthofix International N.V., today reported results for the fourth quarter and full year ended Dec. 31, 2013. For full-year 2013, net sales were $400.5 million, decreasing 11 percent on a reported basis and constant currency basis from $447.6 million in the prior year.
Symphogen, a private biopharmaceutical company developing superior antibody therapeutics to treat cancer, infectious and autoimmune diseases, announced today that second-generation enhancements to the company's SYMPRESS manufacturing and quality control platform will be presented in an oral presentation entitled "Recombinant antibody mixtures; optimization of cell line generation and single-batch manufacturing processes" by Dr. Søren K. Rasmussen, Principal Scientist, Symphogen at the upcoming European Society for Animal Cell Technology conference in Vienna on May 17, 2011.
Researchers have developed a risk-scoring system to identify noncritically ill hospital patients most likely to benefit from prophylactic acid-suppressive medication.
› Verified 7 days ago
| Entity Name | Broadlawns Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467447508 PECOS PAC ID: 3678466166 Enrollment ID: O20040206000913 |
News Archive
In a paper published in the current issue of the journal Molecular Biology and Evolution , Arizona State University biochemists Jason Raymond, Christopher Staples and Robert Blankenship and Rice University's Janet Siefert do an analysis of the genomes of a large group of bacteria and archaea, comparing in particular similar genes that produce the protein nitrogenase.
Teva Pharmaceutical Industries Ltd. announced today the launch of Olanzapine and Fluoxetine Capsules USP 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg, and 12 mg/50 mg, the Company's generic equivalent of Symbyax.
Orthofix International N.V., today reported results for the fourth quarter and full year ended Dec. 31, 2013. For full-year 2013, net sales were $400.5 million, decreasing 11 percent on a reported basis and constant currency basis from $447.6 million in the prior year.
Symphogen, a private biopharmaceutical company developing superior antibody therapeutics to treat cancer, infectious and autoimmune diseases, announced today that second-generation enhancements to the company's SYMPRESS manufacturing and quality control platform will be presented in an oral presentation entitled "Recombinant antibody mixtures; optimization of cell line generation and single-batch manufacturing processes" by Dr. Søren K. Rasmussen, Principal Scientist, Symphogen at the upcoming European Society for Animal Cell Technology conference in Vienna on May 17, 2011.
Researchers have developed a risk-scoring system to identify noncritically ill hospital patients most likely to benefit from prophylactic acid-suppressive medication.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Donald Lee Harker, DO 3215 Sw Timberline Dr, Ankeny, IA 50023-5412 Ph: (707) 315-3167 | Donald Lee Harker, DO 1111 Duff Ave, Ames, IA 50010-5745 Ph: (515) 239-2151 |
News Archive
In a paper published in the current issue of the journal Molecular Biology and Evolution , Arizona State University biochemists Jason Raymond, Christopher Staples and Robert Blankenship and Rice University's Janet Siefert do an analysis of the genomes of a large group of bacteria and archaea, comparing in particular similar genes that produce the protein nitrogenase.
Teva Pharmaceutical Industries Ltd. announced today the launch of Olanzapine and Fluoxetine Capsules USP 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg, and 12 mg/50 mg, the Company's generic equivalent of Symbyax.
Orthofix International N.V., today reported results for the fourth quarter and full year ended Dec. 31, 2013. For full-year 2013, net sales were $400.5 million, decreasing 11 percent on a reported basis and constant currency basis from $447.6 million in the prior year.
Symphogen, a private biopharmaceutical company developing superior antibody therapeutics to treat cancer, infectious and autoimmune diseases, announced today that second-generation enhancements to the company's SYMPRESS manufacturing and quality control platform will be presented in an oral presentation entitled "Recombinant antibody mixtures; optimization of cell line generation and single-batch manufacturing processes" by Dr. Søren K. Rasmussen, Principal Scientist, Symphogen at the upcoming European Society for Animal Cell Technology conference in Vienna on May 17, 2011.
Researchers have developed a risk-scoring system to identify noncritically ill hospital patients most likely to benefit from prophylactic acid-suppressive medication.
› Verified 7 days ago
Jeffrey A. Drawbond, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1111 Duff Ave, Ames, IA 50010 Phone: 515-239-2182 Fax: 515-239-3665 | |
Dr. Eli D Musselman, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1111 Duff Avenue, Ames, IA 50010 Phone: 515-239-2151 Fax: 515-239-2057 | |
Dr. Matthew Ryan Okland, DO Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1111 Duff Avenue, Mcfarland Clinic Pc, Ames, IA 50010 Phone: 515-239-2182 Fax: 515-239-3665 | |
Dr. Lois Y. Stoltze, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1111 Duff Ave, Ames, IA 50010 Phone: 515-239-2182 Fax: 515-239-3665 | |
Dr. Gregory R. Utesch, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1111 Duff Ave, Ames, IA 50010 Phone: 515-239-2182 Fax: 515-239-3665 | |
Dr. Grant Henry Young, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 1111 Duff Ave, Ames, IA 50010 Phone: 515-239-2151 | |
Dr. Brenda J. Kruse, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1111 Duff Ave, Ames, IA 50010 Phone: 515-239-2182 Fax: 515-239-3665 |